Literature DB >> 26449886

Association of meteorological and geographical factors and risk of initial Pseudomonas aeruginosa acquisition in young children with cystic fibrosis.

K J Psoter1, A J DE Roos2, J Wakefield3, J D Mayer4, M Bryan5, M Rosenfeld6.   

Abstract

Initial infection with the sentinel respiratory pathogen in children with cystic fibrosis (CF), Pseudomonas aeruginosa (Pa), is generally with environmental strains of this ubiquitous organism. The purpose of this study was to evaluate the associations between meteorological and geographical factors and risk of initial Pa acquisition in young children with CF. Using the U.S. Cystic Fibrosis Foundation Patient Registry from 2003 to 2009, 3463 patients met inclusion criteria, of which 48% (n = 1659) acquired Pa during follow-up. From multivariable Weibull regression, increased risk of Pa acquisition was associated with increasing temperature [hazard ratio (HR) per 1 °C: 1·13; 95% confidence interval (CI) 1·08-1·13], dew point (HR per 1 °C: 1·10, 95% CI 1·07-1·13), rainfall (HR per cm: 1·10, 95% CI 1·07-1·12), latitude (HR per 1 °C northing: 1·15, 95% CI 1·11-1·20), longitude (HR per 1 °C easting: 1·01, 95% CI 1·01-1·02) and elevation (HR per 100 m: 1·05, 95% CI 1·03-1·07). These results suggest that environmental factors may play a previously unrecognized role in the aetiology of initial Pa acquisition.

Entities:  

Keywords:  Cystic fibrosis; Pseudomonas; epidemiology; paediatrics; respiratory infections

Mesh:

Year:  2015        PMID: 26449886     DOI: 10.1017/S0950268815002411

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  7 in total

Review 1.  Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.

Authors:  Michael D Parkins; Ranjani Somayaji; Valerie J Waters
Journal:  Clin Microbiol Rev       Date:  2018-08-29       Impact factor: 26.132

Review 2.  Early Lung Disease in Infants and Preschool Children with Cystic Fibrosis. What Have We Learned and What Should We Do about It?

Authors:  Sarath C Ranganathan; Graham L Hall; Peter D Sly; Stephen M Stick; Tonia A Douglas
Journal:  Am J Respir Crit Care Med       Date:  2017-06-15       Impact factor: 21.405

3.  Pseudomonas aeruginosa in the Cystic Fibrosis Lung.

Authors:  John King; Ronan Murphy; Jane C Davies
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

4.  Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosis.

Authors:  Kevin J Psoter; Anneclaire J De Roos; Jon Wakefield; Jonathan D Mayer; Margaret Rosenfeld
Journal:  BMC Infect Dis       Date:  2017-06-09       Impact factor: 3.090

5.  Strong incidence of Pseudomonas aeruginosa on bacterial rrs and ITS genetic structures of cystic fibrosis sputa.

Authors:  Laurence Pages-Monteiro; Romain Marti; Carine Commun; Nolwenn Alliot; Claire Bardel; Helene Meugnier; Michele Perouse-de-Montclos; Philippe Reix; Isabelle Durieu; Stephane Durupt; Francois Vandenesch; Jean Freney; Benoit Cournoyer; Anne Doleans-Jordheim
Journal:  PLoS One       Date:  2017-03-10       Impact factor: 3.240

6.  Seasonal variability in clinical care of COPD outpatients: results from the Andalusian COPD audit.

Authors:  Jose Luis López-Campos; Maria Abad Arranz; Carmen Calero-Acuña; Fernando Romero-Valero; Ruth Ayerbe-García; Antonio Hidalgo-Molina; Ricardo I Aguilar-Pérez-Grovas; Francisco García-Gil; Francisco Casas-Maldonado; Laura Caballero-Ballesteros; María Sánchez-Palop; Dolores Pérez-Tejero; Alejandro Segado Soriano; Jose Calvo-Bonachera; Bárbara Hernández-Sierra; Adolfo Doménech; Macarena Arroyo-Varela; Francisco González-Vargas; Juan J Cruz-Rueda
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-03-03

7.  Mortality Due to Cystic Fibrosis over a 36-Year Period in Spain: Time Trends and Geographic Variations.

Authors:  Ana Villaverde-Hueso; Germán Sánchez-Díaz; Francisco J Molina-Cabrero; Elisa Gallego; Manuel Posada de la Paz; Verónica Alonso-Ferreira
Journal:  Int J Environ Res Public Health       Date:  2019-01-04       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.